RoboSense Wins CES 2020 Innovation Award for Autonomous Vehicle Technology
8.11.2019 12:19:00 EET | Business Wire | Press release
RoboSense http://www.robosense.ai, the world’s leading autonomous driving LiDAR perception solution provider, announced today that it has won the CES 2020 Innovation Award the second year in a row for autonomous vehicle technology. RoboSense won this year’s CES 2020 Innovation Award for the first MEMS-based Smart LiDAR Sensor, the RoboSense RS-LiDAR-M1, winning in the Vehicle Intelligence and Self-Driving Technology category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191108005194/en/
RoboSense RS-LiDAR-M1 (Graphic: Business Wire)
The RoboSense award-winning RS-LiDAR-M1 is the world’s first and only MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC(System on a Chip). The RS-LiDAR-M1 goes beyond traditional LiDAR, providing full data collection and comprehension. As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but also processes road data in real-time, with a built-in AI algorithm and SoC, while at the same time synchronizing high-precision positioning output; road traffic signage; lane markings, driving areas, road curbs, and obstacle detection; tracking; and classification. Also, it is the world’s smallest MEMS-based solid-state LiDAR, providing a low cost, high stability, and superior manufacturability to meet automotive-grade and serial production requirements.
“Driving Safety is the most critical challenge for the Autonomous driving vehicles. Perception is the first sense for the AD vehicles to precept the surrounding environment. To ensure a completely safe perception working in all conditions, LiDAR with smart perception algorithm and supporting functions are indispensable. We are very proud that our smart LiDR sensor concept have been recognized by the customers and different application users, ” said Dr. Leilei Shinohara, RoboSense Vice President of R&D.
The RoboSenseRS-LiDAR-M1 Smart LiDAR Sensor will be on display in the Innovation Awards Showcaseat the upcoming CES 2020. The complete list of CES 2020 Innovation Honorees, including product descriptions and photos, can be found at CES.tech/Innovation. RoboSense will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About CES & CES Innovation Awards
An annual program that celebrates outstanding design, the CES Innovation Awards recognizes the best technology products of the year. The CES Innovation Awards are sponsored by the Consumer Technology Association (CTA)™, owner and producer of CES, the world’s largest and most influential technology event.
CES 2020 will showcase life-changing technology across every major industry. CES provides access to the very latest transformative tech, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports tech, machine learning and more. For the latest news and show announcements, visit CES.tech. Follow CES online at CES.tech and on social.
About RoboSense
Founded in 2014, RoboSense is the world’s leading provider of LiDAR environment perception solutions designed to provide a higher performance, safer, more reliable, and lower cost LiDAR system for autonomous vehicles. RoboSense has entered into strategic partnerships with many top car companies, tier one manufacturers and technology companies with a global reach. For more information about RoboSense, visit: https://www.robosense.ai
Photos:
CES 2020 Innovation Award Honoree Logo: http://www.thomas-pr.com/136/photos/robosenseces2020innovationawardlogo.html
RS-LiDAR-M1 Smart LiDAR Sensor: http://www.thomas-pr.com/136/photos/robosensem1lidar.html
RoboSense Logo: http://www.thomas-pr.com/136/photos/robosenselogo.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005194/en/
Contact information
Press:
Karen Thomas/Eva Yutani
Emails: kthomas@thomaspr.com / eyutani@thomaspr.com
(631) 549-7575 website: http://www.thomaspr.com
Company:
Cassie Gong, Overseas PR Manager
Email: sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom